This is a research study of how a cholesterol medication known as fenofibrate works
differently in people with different genetic backgrounds. "Genetics" refers to certain
things that are passed to a person by their parents, such as eye color or hair color.
Genetic differences lead to people having different eye and hair color. There are also
genetic differences in a protein called liver X receptor-alpha (LXRA), which may be
important in predicting the response to fenofibrate.
This is a double blind crossover study of fenofibrate vs. placebo in healthy volunteers.
The null hypothesis is that over a four week period, fenofibrate (160mg/day orally) is
equivalent to placebo in terms of relative changes in cytokines ENA-78 and MCP-1 over a four
week periods, separated by a four week washout. ENA-78 is a marker of inflammation. See
http://en.wikipedia.org/wiki/CXCL5 for more details.
- Triglycerides equal to or above 150mg/dL or Low HDL (below 44 mg/dl for men or below
54 mg/dl for women)
- Must be able to swallow tablets
- Known Coronary Heart Disease, symptomatic carotid artery disease, abdominal aortic
aneurysm, diabetes, or Framingham risk score above 20%
- Pregnancy, malignancy, liver dysfunction, renal dysfunction, active alcohol abuse,
history of unexplained muscle pain
- Current treatment with lipid lowering therapy, estrogens, androgens, progestins,
thiazide diuretics, beta-blockers, glucocorticoids (other than inhaled),
antihistamines, or chronic anti-inflammatory drugs
- Current treatment with the following the interacting drugs: ursodeoxycholic acid,
ursodiol, cholestyramine, red yeast rice, glyburide, glipizide, warfarin, or